Over 850 Cleansweep Auctions End Tomorrow 06/13 - Bid Now
Over 1050 Total Lots Up For Auction at One Location - NJ 06/14

Lunit touts 100 peer-reviewed papers on AI medical imaging

by Gus Iversen, Editor in Chief | May 21, 2024
Women's Health
Lunit, a leader in AI-powered cancer diagnostics and therapeutics, announced that there have been 100 peer-reviewed research articles published featuring its Lunit INSIGHT suite, a milestone the company says underscores the clinical safety, effectiveness, and efficiency of Lunit’s AI solutions.

Since its first publication in 2018, Lunit has produced 55 papers on lung abnormalities, primarily lung nodules, using Lunit INSIGHT CXR, and 45 papers on breast cancer with Lunit INSIGHT MMG and Lunit INSIGHT DBT. Some of these studies, appearing in journals like The Lancet Digital Health, JAMA Oncology, and Radiology, have set industry benchmarks for AI's potential in medical image analysis.

One notable study in The Lancet Digital Health highlighted the potential of AI to replace one human reader in breast cancer screening. This study led to the implementation of Lunit INSIGHT MMG at Capio S:t Göran Hospital in Sweden, effectively replacing one of the two human readers typically required. This step is significant in addressing Europe's radiologist shortage and improving cancer screening efficiency.

Another key study in Radiology by Radboud University Medical Center in the Netherlands validated multiple AI products for lung nodule detection on chest radiographs. Lunit INSIGHT CXR achieved the highest AUC (Area Under the Curve) of 0.93, surpassing human readers and other AI vendors.

“Publishing 100 papers in six years is not just an academic milestone; it is foundational to our mission to conquer cancer through AI,” said Brandon Suh, CEO of Lunit. “Our collaborations with institutions like Massachusetts General Hospital, NHS Trust, and Karolinska Institute have been instrumental in advancing AI in medical imaging.”

Lunit's work demonstrates AI’s practical impact in various medical settings, including Europe's double-reading breast cancer screening systems. Looking ahead, Lunit remains committed to pioneering innovations through research, enhancing patient outcomes, and empowering healthcare providers with accurate and efficient cancer detection tools.

You Must Be Logged In To Post A Comment